¿ Axys Pharmaceuticals Inc., of South San Francisco, appointed Paul Hastings president and chief executive officer effective Jan. 1. Hastings is the former president of Chiron BioPharmaceuticals, a division of Chiron Corp., of Emeryville, Calif.
¿ Biolex Inc., of Pittsboro, N.C., completed its third round of venture financing, a $6.5 million capitalization led by Franklin Street Capital, Intersouth Partners, Kitty Hawk Capital, the Wakefied Group and Tall Oaks Capital. The company has raised $9.1 million in venture funding to date.
¿ Cangene Corp., of Toronto, said it plans to complete enrollment in a Phase II trial of a hyperimmune anti-hepatitis C product in liver transplant recipients in the first quarter of 2001.
¿ Celera Genomics Inc., of Rockville, Md., and Diversa Corp., of San Diego, entered a collaboration to sequence the genomes of uncultured microorganisms from Diversa's environmental libraries. Financial terms were undisclosed.
¿ Cerus Corp., of Concord, Calif., received final clearance from an independent Data and Safety Monitoring Board to complete enrollment in its Phase III trial of the Intercept Platelet System for viral and pathogen inactivation in platelets. The company is conducting the trial in a collaboration with Baxter Healthcare Corp., of Deerfield, Ill.
¿ Cyclacel Ltd., of Dundee, Scotland, entered an agreement with CV Therapeutics Inc., of Palo Alto, Calif. Cyclacel will screen a library of CV small-molecule compounds using its proprietary assays to determine cancer-inhibition potential. Cyclacel also obtained the opportunity to negotiate exclusive worldwide development and commercialization licenses for selected compounds.
¿ Cytran Inc., of Kirkland, Wash., named William Milligan president and chief operating officer. Milligan is the former CEO of Intellivax International Inc., of Montreal.
¿ CytRx Corp., of Atlanta, received a $2 million payment from Merck & Co. Inc., of Whitehouse Station, N.J., related to Merck's license of CytRx's TranzFect technology. That agreement was entered in early November. Merck also is committed to milestone and product approval payments of up to $4 million.
¿ DepoMed Inc., of Menlo Park, Calif., said DepoMed Development Ltd., a joint venture with Elan Pharmaceuticals plc, of Dublin, Ireland, entered Phase I trials with its first product, an undisclosed therapeutic. The study will evaluate the pharmacokinetics of the product to determine whether it has an extended-release profile.
¿ EraGen Biosciences Inc., of Alachua, Fla., and Sloan-Kettering Cancer Center jointly discovered a new approach for discovering small-molecule-derived or protein-based DNA cleavage agents. The high-throughput screening-compatible method uses common nucleic acid chemistries, the company said, making the technology likely the assay of choice for anticancer drug discovery.
¿ Exact Corp., of Washington, D.C., filed for the sale of 4 million shares at $14 to $16 each in an initial public offering expected to net the company about $54.8 million. Exact focuses on detecting colorectal and other cancers, and plans to trade on Nasdaq under the symbol "EXAS."
¿ Gilead Sciences Inc., of Foster City, Calif., entered an agreement with Glaxo Group Ltd. and Glaxo Wellcome Inc., wholly owned subsidiaries of Glaxo Wellcome plc, of London. The agreement grants Gilead worldwide development and marketing rights to GW1843U89, a Phase I thymidylate synthase inhibitor. Gilead plans to reformulate the anticancer agent as a liposomal agent, immediately initiate preclinical testing and file an investigational new drug application in 2001.
¿ Hemispherx Biopharma Inc., of Philadelphia, entered the first phase of its new relationship with Ie Sung International, of Seoul, South Korea, to facilitate accelerated development of its chronic viral disease clinical program in selected Pacific Rim markets. Terms were not disclosed.
¿ HTS Biosystems Inc., of Hopkinton, Mass., entered a strategic relationship with Mitsubishi Chemical Corp., of Japan. Mitsubishi gets access to HTS' bioanalysis system in the deal, for which financial terms were undisclosed.
¿ Nanogen Inc., of San Diego, entered four developmental site agreements, with Beth Israel Deaconess Medical Center, of Boston; KnowledGENE.com Inc., of Los Angeles; Creighton University School of Medicine, of Omaha, Neb.; and Copenhagen University Hospitals. The sites will focus on expanding the clinical research applications of the company's NanoChip Molecular Biology Workstation through the development of genetic-based tests.
¿ Neurobiological Technologies Inc., of Richmond, Calif., engaged Nexus Health Capital LLC, of New York, as a financial adviser to assist in evaluating the company's strategic alternatives. NTI is a drug development company focused on neuroscience.
¿ Nomos Corp., of Sewickley, Pa., named John Manzetti president and chief operating officer. Manzetti is the company's former executive vice president and chief financial officer.
¿ Paradigm Genetics Inc., of Research Triangle Park, N.C., delivered high-throughput assays to Bayer AG, of Leverkusen, Germany, triggering an undisclosed milestone payment from Bayer. The assays are designed to identify a novel class of herbicides.
¿ Pherin Pharmaceuticals Inc., of Mountain View, Calif., filed for patent protection for a novel receptor gene expressed in the human vomeronasal organ. Pherin said the receptor, the first shown to be expressed in the vomeronasal organ, may be able to be cloned and used in screening assays.
¿ Questcor Pharmaceuticals Inc., of Hayward, Calif., entered an agreement with Ahn-Gook Pharmaceuticals Inc., of Seoul, South Korea, for the marketing of Emitasol in Korea. Questcor will receive an up-front cash payment, a milestone payment and royalties on sales.
¿ Serono SA, of Geneva, Switzerland, received marketing approval in Europe for Luveris, a recombinant human luteinizing hormone for infertility. The company also received a recommendation for marketing authorization from the Committee for Proprietary Medicinal Products for Ovidrelle, a recombinant human chorionic gonadotropin. Ovidrel was approved by the FDA in October, and Serono plans to launch the product in early 2001.
¿ Shearwater Corp., of Huntsville, Ala., and Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., agreed to a collaboration aimed at PEGylating Regeneron's obesity drug Axokine. The agreement provides Shearwater with license fees, royalties and exclusive rights to supply the PEG reagent in exchange for its services.
¿ Structural Bioinformatics Inc., of San Diego, acquired Moldyn Inc., a former subsidiary of Photon Research Associates Inc., of San Diego. Financial details were undisclosed. Moldyn applies Photon's defense-related high-speed computational methods to life science research and bioinformatics.
¿ Teva Pharmaceutical Industries Inc., of Jerusalem, launched Copaxone, its treatment for relapsing-remitting multiple sclerosis, in the UK. The launch is the company's first major European market launch. Copaxone will be jointly marketed in the UK by Teva and Aventis SA, of Frankfurt, Germany.
¿ Vertex Pharmaceuticals Inc., of Cambridge, Mass., promoted Vicki Sato to president. Sato is the former chief scientific officer at Vertex.